Blepharospasm Patient Survey: A Structured Interview Evaluating Previous and Current incobotulinumtoxinA, abobotulinumtoxinA and onabotulinumtoxinA Treatment for Patients With Blepharospasm
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 入组人数
- 124
- 试验地点
- 5
- 主要终点
- Botulinum Toxin Treatment Information
研究概览
简要总结
The purpose of this survey is to collect detailed information on patients treated for blepharospasm with incobotulinumtoxinA, abobotulinumtoxinA and onabotulinumtoxinA, including how often they are treated with botulinum toxin, how long their treatment lasts, how satisfied they are with their treatment, and if there is any improvement in their symptoms with the treatment.
详细描述
This study is open to males and females > 18 years and < 81 years with a clinical diagnosis of blepharospasm.
研究设计
- 研究类型
- Observational
- 观察模型
- Other
- 时间视角
- Other
入排标准
- 年龄范围
- 18 Years 至 81 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Male or female subject aged > 18 years and < 81 years
- •Documented clinical diagnosis of blepharospasm
- •Currently receiving incobotulinumtoxinA, abobotulinumtoxinA or onabotulinumtoxinA
排除标准
- •Previous treatment with rimabotulinumtoxinB in the last 2 treatment cycles
结局指标
主要结局
Botulinum Toxin Treatment Information
时间窗: This is a single, structured interview about experiences with Botulinum Toxins
The following information for patients treated for blepharospasm with incobotulinumtoxinA, abobotulinumtoxinA, or onabotulinumtoxinA treatment is collected: (1) botulinum treatment information such as intervals for botulinum injections, physician's rationale for injection interval, overall experience with botulinum toxin injections (onset, maximum effect, decline of effect), current injection cycle experience (current satisfaction, satisfaction at maximum effect, and visual analog scale (VAS) of current health status); and (2) disability status using the Blepharospasm Disability Index (BSDI) and the Jankovic Rating Scale (JRS)
次要结局
未报告次要终点